Fidelity Growth Partners To Invest $10M In China’s Eye Bright Medical

Fidelity Growth Partners, the venture capital and private equity arm of Fidelity Worldwide Investment, says it has agreed to invest RMB62.5 million (US$10 million) in Beijing-based ophthalmology products firm Eye Bright Medical Technology Co., Ltd., according to Chinese media reports.

Two entities under Fidelity Growth Partners, Fidelity Growth Partners Asia and Fidelity Biosciences, will make the investment as part of a strategic partnership being established to further expand the business of Eye Bright.

Founded in 2010, Eye Bright makes artificial lens used to treat eye diseases such as cataracts or myopia, as well as injectors and implantation systems.

Having invested in Greater China for over 18 years, Fidelity Growth Partners Asia has previously invested in WuXi Pharmatech, AsiaInfo and iSoftStone.

China Money Network Subscription
China Expert network